Wescott Financial Advisory Group LLC Sells 1,088 Shares of Pfizer Inc. $PFE

Wescott Financial Advisory Group LLC lessened its stake in shares of Pfizer Inc. (NYSE:PFE) by 6.6% in the 1st quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The fund owned 15,293 shares of the biopharmaceutical company’s stock after selling 1,088 shares during the period. Wescott Financial Advisory Group LLC’s holdings in Pfizer were worth $388,000 as of its most recent filing with the Securities & Exchange Commission.

Other hedge funds and other institutional investors have also made changes to their positions in the company. Clarity Asset Management Inc. bought a new position in shares of Pfizer during the 4th quarter valued at about $27,000. Gould Capital LLC boosted its holdings in shares of Pfizer by 97.2% during the 4th quarter. Gould Capital LLC now owns 1,000 shares of the biopharmaceutical company’s stock valued at $27,000 after purchasing an additional 493 shares during the last quarter. GKV Capital Management Co. Inc. bought a new position in shares of Pfizer in the 1st quarter valued at about $27,000. Bayforest Capital Ltd bought a new position in shares of Pfizer in the 1st quarter valued at about $28,000. Finally, North Capital Inc. bought a new position in shares of Pfizer in the 1st quarter valued at about $28,000. Institutional investors own 68.36% of the company’s stock.

Wall Street Analysts Forecast Growth

A number of brokerages recently commented on PFE. UBS Group increased their price target on shares of Pfizer from $24.00 to $25.00 and gave the company a “neutral” rating in a report on Wednesday, April 30th. Morgan Stanley increased their price target on shares of Pfizer from $32.00 to $33.00 and gave the company an “equal weight” rating in a report on Wednesday, August 6th. The Goldman Sachs Group increased their price target on shares of Pfizer from $25.00 to $27.00 and gave the company a “neutral” rating in a report on Wednesday, April 30th. Leerink Partners lowered their price target on shares of Pfizer from $28.00 to $26.00 and set a “market perform” rating for the company in a report on Wednesday, April 30th. Finally, Redburn Atlantic lowered their price target on shares of Pfizer from $29.00 to $27.00 and set a “neutral” rating for the company in a report on Wednesday, April 30th. Two investment analysts have rated the stock with a Strong Buy rating, four have assigned a Buy rating, eleven have assigned a Hold rating and one has issued a Sell rating to the company. According to MarketBeat, Pfizer presently has a consensus rating of “Hold” and a consensus price target of $28.12.

Pfizer Stock Performance

Pfizer stock opened at $25.7060 on Friday. The company has a debt-to-equity ratio of 0.65, a current ratio of 1.16 and a quick ratio of 0.85. Pfizer Inc. has a 1-year low of $20.92 and a 1-year high of $30.43. The firm has a market capitalization of $146.15 billion, a P/E ratio of 13.67, a price-to-earnings-growth ratio of 0.90 and a beta of 0.52. The company’s 50-day moving average is $24.68 and its 200 day moving average is $24.42.

Pfizer (NYSE:PFE) last issued its earnings results on Tuesday, August 5th. The biopharmaceutical company reported $0.78 EPS for the quarter, topping analysts’ consensus estimates of $0.58 by $0.20. The business had revenue of $14.65 billion for the quarter, compared to analyst estimates of $13.43 billion. Pfizer had a net margin of 16.84% and a return on equity of 21.42%. The company’s quarterly revenue was up 10.3% compared to the same quarter last year. During the same period last year, the company posted $0.60 earnings per share. Pfizer has set its FY 2025 guidance at 2.900-3.100 EPS. Research analysts forecast that Pfizer Inc. will post 2.95 EPS for the current year.

Pfizer Announces Dividend

The business also recently announced a quarterly dividend, which will be paid on Tuesday, September 2nd. Stockholders of record on Friday, July 25th will be given a dividend of $0.43 per share. The ex-dividend date of this dividend is Friday, July 25th. This represents a $1.72 dividend on an annualized basis and a dividend yield of 6.7%. Pfizer’s dividend payout ratio (DPR) is 91.49%.

Pfizer Company Profile

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.